MedTrace Logo

Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg

NCT01819870 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-04-01

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.

Conditions

  • Essential Hypertension
  • Chronic Stable Angina
  • Congestive Heart Failure

Interventions

DRUG

Dilatrend SR capsule 32mg

* 1 capsule, oral, once daily, 7days * over the period I\&II(crossover)

DRUG

Dilatrend IR tablet 25mg

* 1 tablet, oral, once daily, 7days * over the period I\&II(crossover)

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Young-Ran Yoon · Kyungpook National University Hospital Clinical Trial Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-05-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01819870 on ClinicalTrials.gov